Leveraging AI, LLMs and master data management to optimize clinical trial site selection

Clinical trials present significant bottlenecks in pharmaceutical development, with site selection emerging as a critical determinant of success. This article examines how artificial intelligence (AI), large language models (LLMs), and Master Data Management (MDM) systems can be integrated to transform the site selection process. Traditional site selection relies heavily on manual processes, siloed data systems, and subjective decision-making, resulting in suboptimal outcomes and delays. By leveraging AI algorithms to evaluate historical performance across multiple dimensions, assess investigator capabilities, align site demographics with trial requirements, and identify potential risks before they manifest, pharmaceutical companies can move beyond experience-based selection toward data-driven decision-making. MDM systems provide the essential foundation by creating unified data repositories, implementing governance protocols, and enabling real-time performance monitoring. The synergistic integration of these technologies delivers substantial benefits including accelerated site identification, enhanced performance forecasting, compressed activation timelines, optimized patient recruitment, improved diversity and inclusion, proactive risk management, and significant cost avoidance. A phased implementation roadmap offers organizations a structured path to realize these benefits while ensuring sustainable value creation.